Moderna’s pioneering COVID shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) ...

Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

Moderna has been scaling back its financial targets as demand for its Covid shot has waned post-pandemic and its second product, an RSV shot, has gained little traction so far. The company is also ...

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.